Download PDF
Semin Thromb Hemost 2021; 47(03): 261-273
DOI: 10.1055/s-0041-1724118
Review Article

Heparan Sulfate Proteoglycans in Diabetes

Linda M. Hiebert
1   Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Diabetes is a complex disorder responsible for the mortality and morbidity of millions of individuals worldwide. Although many approaches have been used to understand and treat diabetes, the role of proteoglycans, in particular heparan sulfate proteoglycans (HSPGs), has only recently received attention. The HSPGs are heterogeneous, highly negatively charged, and are found in all cells primarily attached to the plasma membrane or present in the extracellular matrix (ECM). HSPGs are involved in development, cell migration, signal transduction, hemostasis, inflammation, and antiviral activity, and regulate cytokines, chemokines, growth factors, and enzymes. Hyperglycemia, accompanying diabetes, increases reactive oxygen species and upregulates the enzyme heparanase that degrades HSPGs or affects the synthesis of the HSPGs altering their structure. The modified HSPGs in the endothelium and ECM in the blood vessel wall contribute to the nephropathy, cardiovascular disease, and retinopathy seen in diabetes. Besides the blood vessel, other cells and tissues in the heart, kidney, and eye are affected by diabetes. Although not well understood, the adipose tissue, intestine, and brain also reveal HSPG changes associated with diabetes. Further, HSPGs are significantly involved in protecting the β cells of the pancreas from autoimmune destruction and could be a focus of prevention of type I diabetes. In some circumstances, HSPGs may contribute to the pathology of the disease. Understanding the role of HSPGs and how they are modified by diabetes may lead to new treatments as well as preventative measures to reduce the morbidity and mortality associated with this complex condition.

Keywords

diabetes - heparan sulfate proteoglycans - heparanase


Publication History

Article published online:
01 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Lindahl U, Kjellén L. Pathophysiology of heparan sulphate: many diseases, few drugs. J Intern Med 2013; 273 (06) 555-571
    CrossrefPubMedGoogle Scholar
  • 2 Rivara S, Milazzo FM, Giannini G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem 2016; 8 (06) 647-680
    CrossrefPubMedGoogle Scholar
  • 3 Shriver Z, Capila I, Venkataraman G, Sasisekharan R. Heparin and heparan sulfate: analyzing structure and microheterogeneity. Handb Exp Pharmacol 2012; 207: 159-176
    CrossrefPubMedGoogle Scholar
  • 4 Parish CR, Freeman C, Ziolkowski AF. et al. Unexpected new roles for heparanase in type 1 diabetes and immune gene regulation. Matrix Biol 2013; 32 (05) 228-233
    CrossrefPubMedGoogle Scholar
  • 5 Gallagher J. Fell-Muir lecture: heparan sulphate and the art of cell regulation: a polymer chain conducts the protein orchestra. Int J Exp Pathol 2015; 96 (04) 203-231
    CrossrefPubMedGoogle Scholar
  • 6 Gondelaud F, Ricard-Blum S. Structures and interactions of syndecans. FEBS J 2019; 286 (15) 2994-3007
    CrossrefPubMedGoogle Scholar
  • 7 Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development 2012; 139 (20) 3693-3709
    CrossrefPubMedGoogle Scholar
  • 8 Traister A, Shi W, Filmus J. Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochem J 2008; 410 (03) 503-511
    CrossrefPubMedGoogle Scholar
  • 9 Kolluri A, Ho M. The role of glypican-3 in regulating Wnt, YAP, and Hedgehog in liver cancer. Front Oncol 2019; 9: 708
    CrossrefPubMedGoogle Scholar
  • 10 Ebong EE, Lopez-Quintero SV, Rizzo V, Spray DC, Tarbell JM. Shear-induced endothelial NOS activation and remodeling via heparan sulfate, glypican-1, and syndecan-1. Integr Biol 2014; 6 (03) 338-347
    CrossrefPubMedGoogle Scholar
  • 11 Okamoto K, Honda K, Doi K. et al. Glypican-5 increases susceptibility to nephrotic damage in diabetic kidney. Am J Pathol 2015; 185 (07) 1889-1898
    CrossrefPubMedGoogle Scholar
  • 12 Farach-Carson MC, Warren CR, Harrington DA, Carson DD. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol 2014; 34: 64-79
    CrossrefPubMedGoogle Scholar
  • 13 Martinez JR, Dhawan A, Farach-Carson MC. Modular proteoglycan perlecan/HSPG2: Mutations, phenotypes, and functions. Genes (Basel) 2018; 9 (11) 1-14
    CrossrefPubMedGoogle Scholar
  • 14 Whitelock JM, Melrose J, Iozzo RV. Diverse cell signaling events modulated by perlecan. Biochemistry 2008; 47 (43) 11174-11183
    CrossrefPubMedGoogle Scholar
  • 15 Heljasvaara R, Aikio M, Ruotsalainen H, Pihlajaniemi T. Collagen XVIII in tissue homeostasis and dysregulation - lessons learned from model organisms and human patients. Matrix Biol 2017; 57–58: 55-75
    CrossrefPubMedGoogle Scholar
  • 16 Daniels MP. The role of agrin in synaptic development, plasticity and signaling in the central nervous system. Neurochem Int 2012; 61 (06) 848-853
    CrossrefPubMedGoogle Scholar
  • 17 Miner JH. The glomerular basement membrane. Exp Cell Res 2012; 318 (09) 973-978
    CrossrefPubMedGoogle Scholar
  • 18 Haimov-Kochman R, Friedmann Y, Prus D. et al. Localization of heparanase in normal and pathological human placenta. Mol Hum Reprod 2002; 8 (06) 566-573
    CrossrefPubMedGoogle Scholar
  • 19 Kosir MA, Foley-Loudon PA, Finkenauer R, Tennenberg SD. Multiple heparanases are expressed in polymorphonuclear cells. J Surg Res 2002; 103 (01) 100-108
    CrossrefPubMedGoogle Scholar
  • 20 Sotnikov I, Hershkoviz R, Grabovsky V. et al. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004; 172 (09) 5185-5193
    CrossrefPubMedGoogle Scholar
  • 21 Vlodavsky I, Eldor A, Haimovitz-Friedman A. et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12 (02) 112-127
    PubMedGoogle Scholar
  • 22 Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5 (07) 803-809
    CrossrefPubMedGoogle Scholar
  • 23 Vlodavsky I, Friedmann Y, Elkin M. et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5 (07) 793-802
    CrossrefPubMedGoogle Scholar
  • 24 McKenzie E, Tyson K, Stamps A. et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 2000; 276 (03) 1170-1177
    CrossrefPubMedGoogle Scholar
  • 25 Gingis-Velitski S, Zetser A, Kaplan V. et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 2004; 279 (42) 44084-44092
    CrossrefPubMedGoogle Scholar
  • 26 Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38 (12) 2018-2039
    CrossrefPubMedGoogle Scholar
  • 27 Gutter-Kapon L, Alishekevitz D, Shaked Y. et al. Heparanase is required for activation and function of macrophages. Proc Natl Acad Sci U S A 2016; 113 (48) E7808-E7817
    CrossrefPubMedGoogle Scholar
  • 28 Bame KJ. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 2001; 11 (06) 91R-98R
    CrossrefPubMedGoogle Scholar
  • 29 Vlodavsky I, Blich M, Li JP, Sanderson RD, Ilan N. Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol 2013; 32 (05) 241-251
    CrossrefPubMedGoogle Scholar
  • 30 Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012; 2 (01) a006429
    PubMedGoogle Scholar
  • 31 Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 1999; 277 (02) H508-H514
    PubMedGoogle Scholar
  • 32 Haraldsson B, Jeansson M. Glomerular filtration barrier. Curr Opin Nephrol Hypertens 2009; 18 (04) 331-335
    CrossrefPubMedGoogle Scholar
  • 33 Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 2007; 454 (03) 345-359
    CrossrefPubMedGoogle Scholar
  • 34 Bashandy GM. Implications of recent accumulating knowledge about endothelial glycocalyx on anesthetic management. J Anesth 2015; 29 (02) 269-278
    CrossrefPubMedGoogle Scholar
  • 35 Kolálová H, AmbrRzová B, Švihálková-Šindlerová L, Klinke A, Kubala L. Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediators Inflamm 2014; 2014 (05) 1-17
    CrossrefPubMedGoogle Scholar
  • 36 Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res 2003; 93 (10) e136-e142
    CrossrefPubMedGoogle Scholar
  • 37 Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol 2018; 38 (07) 1427-1439
    CrossrefPubMedGoogle Scholar
  • 38 Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol 2003; 23 (09) 1541-1547
    CrossrefPubMedGoogle Scholar
  • 39 Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011; 254 (02) 194-200
    CrossrefPubMedGoogle Scholar
  • 40 Condomitti G, de Wit J. Heparan sulfate proteoglycans as emerging players in synaptic specificity. Front Mol Neurosci 2018; 11: 14
    CrossrefPubMedGoogle Scholar
  • 41 Rawshani A, Rawshani A, Franzén S. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379 (07) 633-644
    CrossrefPubMedGoogle Scholar
  • 42 Schmidt AM. Diabetes mellitus and cardiovascular disease: emerging therapeutic approaches. Arterioscler Thromb Vasc Biol 2019; 39 (04) 558-568
    CrossrefPubMedGoogle Scholar
  • 43 Nishinaka T, Mori S, Yamazaki Y. et al. A comparative study of sulphated polysaccharide effects on advanced glycation end-product uptake and scavenger receptor class A level in macrophages. Diabetes Vasc Dis Res 2020; 17 (01) 1479164119896975
    CrossrefPubMedGoogle Scholar
  • 44 Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114 (06) 597-605
    CrossrefPubMedGoogle Scholar
  • 45 Han J, Mandal AK, Hiebert LM. Endothelial cell injury by high glucose and heparanase is prevented by insulin, heparin and basic fibroblast growth factor. Cardiovasc Diabetol 2005; 4 (12) 12
    CrossrefPubMedGoogle Scholar
  • 46 Maxhimer JB, Somenek M, Rao G. et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005; 54 (07) 2172-2178
    CrossrefPubMedGoogle Scholar
  • 47 Han J, Woytowich AE, Mandal AK, Hiebert LM. Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med (Maywood) 2007; 232 (07) 927-934
    PubMedGoogle Scholar
  • 48 Wang F, Kim MS, Puthanveetil P. et al. Endothelial heparanase secretion after acute hypoinsulinemia is regulated by glucose and fatty acid. Am J Physiol Heart Circ Physiol 2009; 296 (04) H1108-H1116
    CrossrefPubMedGoogle Scholar
  • 49 Wang F, Wang Y, Kim MS. et al. Glucose-induced endothelial heparanase secretion requires cortical and stress actin reorganization. Cardiovasc Res 2010; 87 (01) 127-136
    CrossrefPubMedGoogle Scholar
  • 50 Han J, Zhang F, Xie J, Linhardt RJ, Hiebert LM. Changes in cultured endothelial cell glycosaminoglycans under hyperglycemic conditions and the effect of insulin and heparin. Cardiovasc Diabetol 2009; 8 (46) 46
    CrossrefPubMedGoogle Scholar
  • 51 Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000; 148 (04) 811-824
    CrossrefPubMedGoogle Scholar
  • 52 Annecke T, Fischer J, Hartmann H. et al. Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs ischaemia/reperfusion. Br J Anaesth 2011; 107 (05) 679-686
    CrossrefPubMedGoogle Scholar
  • 53 Qin Q, Niu J, Wang Z, Xu W, Qiao Z, Gu Y. Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol 2013; 12 (37) 37
    CrossrefPubMedGoogle Scholar
  • 54 An XF, Zhou L, Jiang PJ. et al. Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor. Mol Cell Biochem 2011; 354 (1–2): 47-55
    CrossrefPubMedGoogle Scholar
  • 55 Baker AB, Chatzizisis YS, Beigel R. et al. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 2010; 213 (02) 436-442
    CrossrefPubMedGoogle Scholar
  • 56 Gil N, Goldberg R, Neuman T. et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012; 61 (01) 208-216
    CrossrefPubMedGoogle Scholar
  • 57 Reine TM, Kusche-Gullberg M, Feta A, Jenssen T, Kolset SO. Heparan sulfate expression is affected by inflammatory stimuli in primary human endothelial cells. Glycoconj J 2012; 29 (01) 67-76
    CrossrefPubMedGoogle Scholar
  • 58 Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005; 280 (21) 20457-20466
    CrossrefPubMedGoogle Scholar
  • 59 Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15 (04) 6184-6223
    CrossrefPubMedGoogle Scholar
  • 60 Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84 (04) 1381-1478
    CrossrefPubMedGoogle Scholar
  • 61 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11 (02) 98-107
    CrossrefPubMedGoogle Scholar
  • 62 Rees MD, Kennett EC, Whitelock JM, Davies MJ. Oxidative damage to extracellular matrix and its role in human pathologies. Free Radic Biol Med 2008; 44 (12) 1973-2001
    CrossrefPubMedGoogle Scholar
  • 63 Kanwar YS, Veis A, Kimura JH, Jakubowski ML. Characterization of heparan sulfate-proteoglycan of glomerular basement membranes. Proc Natl Acad Sci U S A 1984; 81 (03) 762-766
    CrossrefPubMedGoogle Scholar
  • 64 Parthasarathy N, Gotow LF, Bottoms JD. et al. Influence of glucose on production and N-sulfation of heparan sulfate in cultured adipocyte cells. Mol Cell Biochem 2000; 213 (1–2): 1-9
    CrossrefPubMedGoogle Scholar
  • 65 Groffen AJ, Ruegg MA, Dijkman H. et al. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998; 46 (01) 19-27
    CrossrefPubMedGoogle Scholar
  • 66 Morita H, Yoshimura A, Inui K. et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 2005; 16 (06) 1703-1710
    CrossrefPubMedGoogle Scholar
  • 67 Harvey SJ, Jarad G, Cunningham J. et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171 (01) 139-152
    CrossrefPubMedGoogle Scholar
  • 68 Galvis-Ramírez MF, Quintana-Castillo JC, Bueno-Sanchez JC. Novel Insights into the role of glycans in the pathophysiology of glomerular endotheliosis in preeclampsia. Front Physiol 2018; 9: 1470
    CrossrefPubMedGoogle Scholar
  • 69 Jeansson M, Haraldsson B. Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 2006; 290 (01) F111-F116
    CrossrefPubMedGoogle Scholar
  • 70 Kanwar YS, Wada J, Sun L. et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233 (01) 4-11
    CrossrefPubMedGoogle Scholar
  • 71 Celie JW, Reijmers RM, Slot EM. et al. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol 2008; 294 (01) F253-F263
    CrossrefPubMedGoogle Scholar
  • 72 Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Impact of heparanase on renal fibrosis. J Transl Med 2015; 13: 181
    CrossrefPubMedGoogle Scholar
  • 73 Lepedda AJ, De Muro P, Capobianco G, Formato M. Significance of urinary glycosaminoglycans/proteoglycans in the evaluation of type 1 and type 2 diabetes complications. J Diabetes Complications 2017; 31 (01) 149-155
    CrossrefPubMedGoogle Scholar
  • 74 Tamsma JT, van den Born J, Bruijn JA. et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37 (03) 313-320
    CrossrefPubMedGoogle Scholar
  • 75 van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 1992; 41 (01) 115-123
    CrossrefPubMedGoogle Scholar
  • 76 Lee EY, Kim SH, Whang SK, Hwang KY, Yang JO, Hong SY. Isolation, identification, and quantitation of urinary glycosaminoglycans. Am J Nephrol 2003; 23 (03) 152-157
    CrossrefPubMedGoogle Scholar
  • 77 Zhao T, Lu X, Davies NM. et al. Diabetes results in structural alteration of chondroitin sulfate in the urine. J Pharm Pharm Sci 2013; 16 (03) 486-493
    CrossrefPubMedGoogle Scholar
  • 78 Joladarashi D, Salimath PV, Chilkunda ND. Diabetes results in structural alteration of chondroitin sulfate/dermatan sulfate in the rat kidney: effects on the binding to extracellular matrix components. Glycobiology 2011; 21 (07) 960-972
    CrossrefPubMedGoogle Scholar
  • 79 van den Hoven MJ, Rops AL, Bakker MA. et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70 (12) 2100-2108
    CrossrefPubMedGoogle Scholar
  • 80 Wijnhoven TJ, van den Hoven MJ, Ding H. et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008; 51 (02) 372-382
    CrossrefPubMedGoogle Scholar
  • 81 Rops AL, van den Hoven MJ, Veldman BA. et al. Urinary heparanase activity in patients with type 1 and type 2 diabetes. Nephrol Dial Transplant 2012; 27 (07) 2853-2861
    CrossrefPubMedGoogle Scholar
  • 82 Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One 2011; 6 (02) e17312
    CrossrefPubMedGoogle Scholar
  • 83 Shafat I, Agbaria A, Boaz M. et al. Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One 2012; 7 (09) e44076
    CrossrefPubMedGoogle Scholar
  • 84 Raats CJ, Van Den Born J, Berden JHM. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57 (02) 385-400
    CrossrefPubMedGoogle Scholar
  • 85 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32 (04) 219-226
    CrossrefPubMedGoogle Scholar
  • 86 Okamoto K, Tokunaga K, Doi K. et al. Common variation in GPC5 is associated with acquired nephrotic syndrome. Nat Genet 2011; 43 (05) 459-463
    CrossrefPubMedGoogle Scholar
  • 87 Tonolo G, Cherchi S. Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis 2014; 7: 107-115
    CrossrefPubMedGoogle Scholar
  • 88 Masola V, Gambaro G, Tibaldi E. et al. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 2012; 287 (02) 1478-1488
    CrossrefPubMedGoogle Scholar
  • 89 Zhou M, Liu J, Hao Y. et al; CCC-ACS Investigators. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovasc Diabetol 2018; 17 (01) 147
    CrossrefPubMedGoogle Scholar
  • 90 O'Brien KD, Ferguson M, Gordon D, Deeb SS, Chait A. Lipoprotein lipase is produced by cardiac myocytes rather than interstitial cells in human myocardium. Arterioscler Thromb 1994; 14 (09) 1445-1451
    CrossrefPubMedGoogle Scholar
  • 91 Wang Y, Chiu AP, Neumaier K. et al. Endothelial cell heparanase taken up by cardiomyocytes regulates lipoprotein lipase transfer to the coronary lumen after diabetes. Diabetes 2014; 63 (08) 2643-2655
    CrossrefPubMedGoogle Scholar
  • 92 Young SG, Davies BS, Voss CV. et al. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res 2011; 52 (11) 1869-1884
    CrossrefPubMedGoogle Scholar
  • 93 Pulinilkunnil T, Qi D, Ghosh S. et al. Circulating triglyceride lipolysis facilitates lipoprotein lipase translocation from cardiomyocyte to myocardial endothelial lining. Cardiovasc Res 2003; 59 (03) 788-797
    CrossrefPubMedGoogle Scholar
  • 94 Wang Y, Zhang D, Chiu AP. et al. Endothelial heparanase regulates heart metabolism by stimulating lipoprotein lipase secretion from cardiomyocytes. Arterioscler Thromb Vasc Biol 2013; 33 (05) 894-902
    CrossrefPubMedGoogle Scholar
  • 95 Chiu AP, Bierende D, Lal N. et al. Dual effects of hyperglycemia on endothelial cells and cardiomyocytes to enhance coronary LPL activity. Am J Physiol Heart Circ Physiol 2018; 314 (01) H82-H94
    CrossrefPubMedGoogle Scholar
  • 96 Zhang D, Wan A, Chiu AP. et al. Hyperglycemia-induced secretion of endothelial heparanase stimulates a vascular endothelial growth factor autocrine network in cardiomyocytes that promotes recruitment of lipoprotein lipase. Arterioscler Thromb Vasc Biol 2013; 33 (12) 2830-2838
    CrossrefPubMedGoogle Scholar
  • 97 Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993; 36 (04) 316-322
    CrossrefPubMedGoogle Scholar
  • 98 Brown DM, Klein DJ, Michael AF, Oegema TR. 35S-glycosaminoglycan and 35S-glycopeptide metabolism by diabetic glomeruli and aorta. Diabetes 1982; 31 (5, Pt 1): 418-425
    CrossrefPubMedGoogle Scholar
  • 99 Vlodavsky I, Iozzo RV, Sanderson RD. Heparanase: multiple functions in inflammation, diabetes and atherosclerosis. Matrix Biol 2013; 32 (05) 220-222
    CrossrefPubMedGoogle Scholar
  • 100 Blich M, Golan A, Arvatz G. et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 2013; 33 (02) e56-e65
    CrossrefPubMedGoogle Scholar
  • 101 Osterholm C, Folkersen L, Lengquist M. et al. Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 2013; 226 (01) 67-73
    CrossrefPubMedGoogle Scholar
  • 102 Aldi S, Eriksson L, Kronqvist M. et al. Dual roles of heparanase in human carotid plaque calcification. Atherosclerosis 2019; 283: 127-136
    CrossrefPubMedGoogle Scholar
  • 103 Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010; 95 (11) 1927-1934
    CrossrefPubMedGoogle Scholar
  • 104 Kunjathoor VV, Chiu DS, O'Brien KD, LeBoeuf RC. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22 (03) 462-468
    CrossrefPubMedGoogle Scholar
  • 105 Xu YX, Ashline D, Liu L. et al. The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis. J Lipid Res 2015; 56 (02) 266-276
    CrossrefPubMedGoogle Scholar
  • 106 Tran-Lundmark K, Tran PK, Paulsson-Berne G. et al. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res 2008; 103 (01) 43-52
    PubMedGoogle Scholar
  • 107 Vogl-Willis CA, Edwards IJ. High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 2004; 1672 (01) 36-45
    CrossrefPubMedGoogle Scholar
  • 108 Vogl-Willis CA, Edwards IJ. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol 2004; 24 (05) 858-863
    CrossrefPubMedGoogle Scholar
  • 109 Xie J, Li R, Wu H. et al. Advanced glycation endproducts impair endothelial progenitor cell migration and homing via syndecan 4 shedding. Stem Cells 2017; 35 (02) 522-531
    CrossrefPubMedGoogle Scholar
  • 110 Zeng BJ, Mortimer BC, Martins IJ, Seydel U, Redgrave TG. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 1998; 39 (04) 845-860
    CrossrefPubMedGoogle Scholar
  • 111 Stanford KI, Bishop JR, Foley EM. et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 2009; 119 (11) 3236-3245
    PubMedGoogle Scholar
  • 112 Wang JB, Zhang YJ, Zhang Y. et al. Negative correlation between serum syndecan-1 and apolipoprotein A1 in patients with type 2 diabetes mellitus. Acta Diabetol 2013; 50 (02) 111-115
    CrossrefPubMedGoogle Scholar
  • 113 Park PJ, Shukla D. Role of heparan sulfate in ocular diseases. Exp Eye Res 2013; 110: 1-9
    CrossrefPubMedGoogle Scholar
  • 114 Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51 (09) 1574-1580
    CrossrefPubMedGoogle Scholar
  • 115 Clark SJ, Keenan TDL, Fielder HL. et al. Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. Invest Ophthalmol Vis Sci 2011; 52 (09) 6511-6521
    CrossrefPubMedGoogle Scholar
  • 116 Tiwari V, Clement C, Xu D. et al. Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts. J Virol 2006; 80 (18) 8970-8980
    CrossrefPubMedGoogle Scholar
  • 117 Coulson-Thomas VJ, Chang SH, Yeh LK. et al. Loss of corneal epithelial heparan sulfate leads to corneal degeneration and impaired wound healing. Invest Ophthalmol Vis Sci 2015; 56 (05) 3004-3014
    CrossrefPubMedGoogle Scholar
  • 118 Nishiguchi KM, Ushida H, Tomida D, Kachi S, Kondo M, Terasaki H. Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy. Mol Vis 2013; 19: 1125-1131
    PubMedGoogle Scholar
  • 119 Bollineni JS, Alluru I, Reddi AS. Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr Eye Res 1997; 16 (02) 127-130
    CrossrefPubMedGoogle Scholar
  • 120 Nishiguchi KM, Kataoka K, Kachi S, Komeima K, Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS One 2010; 5 (10) e13493
    CrossrefPubMedGoogle Scholar
  • 121 Pessentheiner AR, Ducasa GM, Gordts PLSM. Proteoglycans in obesity-associated metabolic dysfunction and meta-inflammation. Front Immunol 2020; 11: 769
    Google Scholar
  • 122 Angsana J, Chen J, Smith S. et al. Syndecan-1 modulates the motility and resolution responses of macrophages. Arterioscler Thromb Vasc Biol 2015; 35 (02) 332-340
    CrossrefPubMedGoogle Scholar
  • 123 Ussar S, Bezy O, Blüher M, Kahn CR. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 2012; 61 (09) 2289-2298
    CrossrefPubMedGoogle Scholar
  • 124 Li K, Xu X, Hu W. et al. Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2014; 51 (06) 981-990
    CrossrefPubMedGoogle Scholar
  • 125 Yamashita Y, Nakada S, Yoshihara T. et al. Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle. Sci Rep 2018; 8 (01) 7766
    CrossrefPubMedGoogle Scholar
  • 126 Bode L, Salvestrini C, Park PW. et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008; 118 (01) 229-238
    CrossrefPubMedGoogle Scholar
  • 127 Yamamoto S, Nakase H, Matsuura M. et al. Heparan sulfate on intestinal epithelial cells plays a critical role in intestinal crypt homeostasis via Wnt/β-catenin signaling. Am J Physiol Gastrointest Liver Physiol 2013; 305 (03) G241-G249
    CrossrefPubMedGoogle Scholar
  • 128 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013; 4 (03) 51-63
    CrossrefPubMedGoogle Scholar
  • 129 Bosi E, Molteni L, Radaelli MG. et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006; 49 (12) 2824-2827
    CrossrefPubMedGoogle Scholar
  • 130 Qing Q, Zhang S, Chen Y, Li R, Mao H, Chen Q. High glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression. J Cell Mol Med 2015; 19 (06) 1366-1374
    CrossrefPubMedGoogle Scholar
  • 131 Trout AL, Rutkai I, Biose IJ, Bix GJ. Review of alterations in perlecan-associated vascular risk factors in dementia. Int J Mol Sci 2020; 21 (02) 1-19
    CrossrefPubMedGoogle Scholar
  • 132 Sima AA. Encephalopathies: the emerging diabetic complications. Acta Diabetol 2010; 47 (04) 279-293
    CrossrefPubMedGoogle Scholar
  • 133 Ando Y, Okada H, Takemura G. et al. Brain-specific ultrastructure of capillary endothelial glycocalyx and its possible contribution for blood brain barrier. Sci Rep 2018; 8 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 134 Prasad S, Sajja RK, Naik P, Cucullo L. Diabetes mellitus and blood-brain barrier dysfunction: an overview. J Pharmacovigil 2014; 2 (02) 125
    PubMedGoogle Scholar
  • 135 Pahakis MY, Kosky JR, Dull RO, Tarbell JM. The role of endothelial glycocalyx components in mechanotransduction of fluid shear stress. Biochem Biophys Res Commun 2007; 355 (01) 228-233
    CrossrefPubMedGoogle Scholar
  • 136 Sandeep MS, Nandini CD. Brain heparan sulphate proteoglycans are altered in developing foetus when exposed to in-utero hyperglycaemia. Metab Brain Dis 2017; 32 (04) 1185-1194
    CrossrefPubMedGoogle Scholar
  • 137 Karlsson-Lindahl L, Schmidt L, Haage D. et al. Heparanase affects food intake and regulates energy balance in mice. PLoS One 2012; 7 (03) e34313
    CrossrefPubMedGoogle Scholar
  • 138 Irving-Rodgers HF, Ziolkowski AF, Parish CR. et al. Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulitis. Diabetologia 2008; 51 (09) 1680-1688
    CrossrefPubMedGoogle Scholar
  • 139 Ziolkowski AF, Popp SK, Freeman C, Parish CR, Simeonovic CJ. Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes. J Clin Invest 2012; 122 (01) 132-141
    CrossrefPubMedGoogle Scholar
  • 140 Simeonovic CJ, Popp SK, Starrs LM. et al. Loss of intra-islet heparan sulfate is a highly sensitive marker of type 1 diabetes progression in humans. PLoS One 2018; 13 (02) e0191360
    CrossrefPubMedGoogle Scholar
  • 141 Packham DK, Wolfe R, Reutens AT. et al; Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23 (01) 123-130
    CrossrefPubMedGoogle Scholar
  • 142 Li R, Xing J, Mu X. et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther 2015; 9: 6275-6283
    PubMedGoogle Scholar